|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.26/-1.57
|
企业价值
164.76M
|
资产负债 |
每股账面净值
0.95
|
现金流量 |
现金流量率
--
|
损益表 |
收益
100.56M
|
每股收益
0.96
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

同行比较之报价最少15分钟延迟
业务概览
|
|||
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |